| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cleft lip and palate transmembrane protein 1-like protein, CLPTM1-like protein, Cisplatin resistance-related protein 9, CRR9p, CLPTM1L, CRR9 |
| Entrez GeneID | 81037 |
| WB Predicted band size | 62.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CLPTM1L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 370-399 amino acids from the C-terminal region of human CLPTM1L. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CLPTM1L抗体的3篇参考文献示例(内容基于公开研究概括，非真实文献)：
---
1. **文献名称**: "CLPTM1L overexpression in lung cancer: A biomarker study using immunohistochemistry"
**作者**: Zhang Y, et al.
**摘要**: 该研究通过免疫组化技术分析CLPTM1L蛋白在非小细胞肺癌组织中的表达，发现其高表达与患者预后不良相关，验证了抗体的特异性及临床应用潜力。
2. **文献名称**: "CRR9/CLPTM1L regulates telomerase activity via interaction with TERT"
**作者**: James CD, et al.
**摘要**: 研究利用CLPTM1L抗体进行Western blot和免疫共沉淀实验，揭示CLPTM1L与端粒酶逆转录酶(TERT)的相互作用，调控端粒酶活性及癌细胞增殖机制。
3. **文献名称**: "CLPTM1L variants and DNA damage response: Insights from siRNA and antibody-based silencing"
**作者**: Wang H, et al.
**摘要**: 通过抗体介导的蛋白定位分析，发现CLPTM1L参与DNA损伤修复通路，其缺失导致细胞对化疗药物敏感性增加，提示其在治疗中的潜在靶点价值。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“CLPTM1L antibody”或联系相关领域数据库获取全文。
The CLPTM1L (Cleft Lip and Palate Transmembrane 1-Like) protein, encoded by the CLPTM1L gene located on chromosome 11q13. is a transmembrane protein implicated in cellular processes such as apoptosis regulation, vesicle trafficking, and mitochondrial function. Originally identified as a susceptibility locus for lung and pancreatic cancers, CLPTM1L gained attention due to its frequent co-amplification with the oncogene TMEM16A (ANO1) in multiple cancers. Studies suggest it may promote tumor progression by inhibiting apoptosis, enhancing DNA repair, or modulating cisplatin resistance, though its exact mechanisms remain under investigation.
CLPTM1L antibodies are essential tools for studying its expression patterns, subcellular localization (primarily Golgi apparatus and plasma membrane), and functional roles. Commercial antibodies target specific epitopes, enabling applications like Western blotting, immunohistochemistry, and immunofluorescence. Research using these antibodies has revealed CLPTM1L overexpression in cancers such as lung, ovarian, and oral squamous cell carcinoma, correlating with poor prognosis. However, conflicting reports exist, with some studies indicating tumor-suppressive effects in specific contexts, highlighting its context-dependent behavior.
Recent interest in CLPTM1L antibodies extends to exploring its potential as a therapeutic target or biomarker, particularly given its association with cancer risk variants and therapy resistance. Validation of antibody specificity remains critical due to homology with other transmembrane proteins and splice variants.
×
